15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering BioCryst Pharmaceuticals Inc, 8 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $9.00 to $32.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $21.80 sits 124% above the current $9.74. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.13 next quarter toward $1.00 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy880%
Hold220%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to BioCryst Pharmaceuticals Inc.
As of Jul, 8 of 10 firms rate BCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BCRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $0.12 – $0.13 · 2 analysts · -22% YoY
Next period, 2 analysts expect BioCryst Pharmaceuticals Inc to earn $0.13 a share (range $0.12 – $0.13), versus $0.16 a year earlier. Full-year consensus is $0.66, growing to $1.00 the year after.
REVENUE · NEXT QUARTER
$165.9M
Range $162.6M – $171.0M · 2 analysts · +4% YoY
Revenue is expected to reach $165.9M (range $162.6M – $171.0M), +4.1% year-over-year. Full-year consensus is $669.4M, rising to $726.2M next year.
Top analysts covering BioCryst Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCRX.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$32.00+228.5% to target
Overall win rate
46%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$28.00+187.5% to target
Overall win rate
44%
+ Follow
#3
Jessica Fye
JP Morgan · Rank #64
Hold
$12.00+23.2% to target
Overall win rate
52%
+ Follow
#4
Serge Belanger
Needham · Rank #83
Buy
$16.00+64.3% to target
Overall win rate
48%
+ Follow
#5
Laura Chico
Wedbush · Rank #122
Buy
$21.00+115.6% to target
Overall win rate
40%
+ Follow
BCRX stock forecast FAQ
What is BCRX's average 12-month price target?+
The 10 analysts with a live target average $21.80 for BioCryst Pharmaceuticals Inc over the next 12 months, ranging from a $32.00 high to a $9.00 low.
Is BCRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 8 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BCRX?+
The Street-high target is $32.00 (HC Wainwright & Co.), and the Street-low is $9.00 (Barclays). The average of all 10 active targets is $21.80.
How many Wall Street analysts cover BCRX?+
10 analysts have an active rating on BioCryst Pharmaceuticals Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering BCRX?+
Among analysts who currently cover BCRX, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $32.00 target.
What is BioCryst Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $0.12 – $0.13) across 2 analysts. Full-year EPS is projected at $0.66, rising to $1.00 the following year.
How much revenue is BioCryst Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $165.9M (range $162.6M – $171.0M). Full-year revenue is projected at $669.4M, growing to $726.2M next year.
Have analysts been upgrading or downgrading BCRX lately?+
As of Jul, 8 of 10 firms rate BCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
